id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-314942-eym2rh8v	El Tabaa, Manar Mohammed	New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19	2020-10-01		.txt	text/plain	7634	473	48	Being a highly selective phosphodiesterase-4 inhibitors (PDE4i), roflumilast acts by enhancing the level of cyclic adenosine monophosphate (cAMP), that probably potentiates its anti-inflammatory action via increasing neprilysin (NEP) activity. Because activating NEP was previously reported to mitigate several airway inflammatory ailments; this review thoroughly discusses the proposed NEP-based therapeutic properties of roflumilast, which may be of great importance in curing COVID-19. Additionally, breaking ET-1 by NEP will prolong the anti-inflammatory effect of 716 roflumilast via maintaining the high cAMP level which is underscored to play an 717 important role in improving the immune system of highly risk COVID-19 groups 718 (Graf et al., 1995; Raker et al., 2016) . Degrading ET-1 can also inhibit pulmonary fibrosis via blocking the ET-1-induced transforming growth factor-β1 (TGF-β1), and at the same time, maintain the high level of cAMP which may contribute for long-term anti-inflammatory effect of roflumilast.	./cache/cord-314942-eym2rh8v.txt	./txt/cord-314942-eym2rh8v.txt